armed and accurate engineering cytotoxic t cells for eradication of leukemia武装和准确的工程为根除白血病细胞毒性t细胞.pdfVIP

Radic BMC Biotechnology 2012, 12:6 /1472-6750/12/6 COMMENTARY Open Access Armed and accurate: engineering cytotoxic T cells for eradication of leukemia Marko Radic Abstract Translational medicine depends on a rapid and efficient exchange of results between the bench and the bedside. A recent example from the field of cancer immunotherapy highlights the essential nature of this exchange. Methods have been developed to convert a patient’s cytotoxic T cells into efficient and specific killers of cancer cells in patients with leukemia. By using recombinant DNA techniques, a lentiviral vector was constructed to express chimeric antigen receptors in cytotoxic T cells from patients with advanced chronic lymphocytic leukemia. The purpose of the chimeric receptors was to direct the cytotoxic T cell activity against cells causing the cancer. The effect of infusing the engineered T cells back into the cancer patients was tested in a Phase I trial at the University of Pennsylvania, and the initial results were described in two articles from the research team of Dr. Carl June. The remarkable success of this trial should energize further applications of biotechnology in the development of new cancer immunotherapies. Main Text harnessing of the immune system’s ferocious power to Recent advances in cancer immunotherapy have allowed eliminate an advanced metastatic cancer. the conversion of T cells from leukemia patients into The stunning results were published in two simulta- efficient and specific killers of their own cancer cells. neous journal articles [1,2], one of the reports present- The new technique has been recently tested with ing data from a single patient [1]. The succ